SCHEMBL20447482

SCHEMBL20447482

O=C(O)Nc1nccc(-c2cnc(F)c(Cl)c2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 5/20 0.45
▸ AAK1 Q2M2I8 5/20 0.45
▸ PDGFRB P09619 2/20 0.41
▸ PDGFRA P16234 2/20 0.41
▸ CAMK2D Q13557 2/20 0.40
▸ GSK3B P49841 1/20 0.39
▸ CAMKK2 Q96RR4 1/20 0.39
▸ MAPK8 P45983 1/20 0.38
▸ MAPK10 P53779 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ BCR P11274 1/20 0.38
▸ BRAF P15056 1/20 0.38
▸ MAPK14 Q16539 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21508206 0.86 AAK1 (0.59) KMOAAK1PIK3CAPIK3CBPIK3CG
SCHEMBL20447425 0.86 AAK1 (0.46) KMOAAK1PDGFRBPDGFRACAMK2D
SCHEMBL20447168 0.85 KMO (0.45) KMOAAK1PDGFRBPDGFRACAMK2D
SCHEMBL28479895 0.76 KMO (0.41) KMOAAK1L3MBTL1
SCHEMBL20447299 0.75 AAK1 (0.58) AAK1PDGFRBPDGFRAABL1BCR
SCHEMBL20446925 0.74 AAK1 (0.42) KMOAAK1ABL1BCR
SCHEMBL20447053 0.72 AAK1 (0.85) AAK1
SCHEMBL21508477 0.72 AAK1 (0.59) KMOAAK1ABL1BCR
SCHEMBL20446929 0.71 AAK1 (0.45) KMOAAK1PDGFRBPDGFRACAMKK2
SCHEMBL3143961 0.70 MEN1 (0.52) PIK3CAPIK3CBPIK3CGL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10544120-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-01-28 — — US disclosed
EP-3356340-B1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-10-23 — — EP disclosed
US-20180346440-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-12-06 — — US disclosed
EP-3356340-A1 BIARYL KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2018-08-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180346440-A1 BIARYL KINASE INHIBITORS AAK1, CAMKK1, CAMKK2 KMO 1360/4885AAK1 1/4885PDGFRB 1488/4885
US-10544120-B2 Biaryl kinase inhibitors AAK1, CAMKK1, CAMKK2 KMO 1360/4885AAK1 1/4885PDGFRB 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback